Diagnostic accuracy of a point-of-care urine tenofovir assay, and associations with HIV viraemia and drug resistance among people receiving dolutegravir and efavirenz-based antiretroviral therapy

Diagnostic accuracy of a point-of-care urine tenofovir assay, and associations with HIV viraemia and drug resistance among people receiving dolutegravir and efavirenz-based antiretroviral therapy

<p><strong>Introduction: </strong>Novel point-of-care assays which measure urine tenofovir (TFV) concentrations may have a role in improving adherence monitoring for people living with HIV (PLHIV) receiving antiretroviral therapy (ART). However, further studies of their di...

Full description

Bibliographic Details
Main Authors:	Dorward, J, Lessells, R, Govender, K, Moodley, P, Samsunder, N, Sookrajh, Y, Turner, P, Butler, CC, Hayward, G, Gandhi, M, Drain, PK, Garrett, N
Format:	Journal article
Language:	English
Published:	Wiley 2023

Similar Items

Urine tenofovir and dried blood spot tenofovir diphosphate concentrations and viraemia in people taking efavirenz and dolutegravir based antiretroviral therapy
by: Dorward, J, et al.
Published: (2023)

Viremia and HIV drug resistance among people receiving dolutegravir versus efavirenz-based first-line antiretroviral therapy
by: Dorward, J, et al.
Published: (2024)

Clinical outcomes after Viremia among people receiving dolutegravir vs efavirenz-based first-line antiretroviral therapy in South Africa
by: Asare, K, et al.
Published: (2023)

Point-of-care viral load testing to manage HIV viraemia during the rollout of dolutegravir-based ART in South Africa: a randomised feasibility study (POwER)
by: Dorward, J, et al.
Published: (2023)

Dolutegravir for first-line antiretroviral therapy in low-income and middle-income countries: uncertainties and opportunities for implementation and research
by: Dorward, J, et al.
Published: (2018)

Implementation and outcomes of dolutegravir-based first-line antiretroviral therapy for people with HIV in South Africa: a retrospective cohort study
by: Dorward, J, et al.
Published: (2023)

Virologic efficacy of tenofovir, lamivudine and dolutegravir as second-line antiretroviral therapy in adults failing a tenofovir-based first-line regimen
by: Keene, CM, et al.
Published: (2021)

Recycling tenofovir in second-line antiretroviral treatment with dolutegravir: outcomes and viral load trajectories to 72 weeks
by: Keene, CM, et al.
Published: (2023)

Simplifying TREAtment and Monitoring for HIV (STREAM HIV): protocol for a randomised controlled trial of point-of-care urine tenofovir and viral load testing to improve HIV outcomes
by: Bardon, AR, et al.
Published: (2021)

Early antiretroviral therapy is associated with better viral suppression and less HIV drug resistance after implementation of universal treatment in South Africa
by: Dorward, J, et al.
Published: (2019)

Clinic-based evaluation of a point-of-care creatinine assay to screen for renal impairment among HIV-positive patients receiving tenofovir disoproxil fumarate
by: Dorward, J, et al.
Published: (2018)

AntiRetroviral Therapy In Second-line: investigating Tenofovir-lamivudine-dolutegravir (ARTIST): protocol for a randomised controlled trial
by: Zhao, Y, et al.
Published: (2021)

Diagnostic accuracy of the rapid Xpert HIV-1 Viral Load XC, Xpert HIV-1 Viral Load & m-PIMA HIV-1/2 Viral Load in South African clinics
by: Dorward, J, et al.
Published: (2022)

Protocol for a randomised feasibility study of Point-Of-care HIV viral load testing to Enhance Re-suppression in South Africa: the POwER study
by: Dorward, JJ, et al.
Published: (2021)

Hypophosphataemia with non-tenofovir-containing antiretroviral therapy.
by: Wainwright, E, et al.
Published: (2013)

Dolutegravir in sub-Saharan Africa: context is crucial
by: Dorward, J, et al.
Published: (2018)

Delivery of community-based antiretroviral therapy to maintain viral suppression and retention in care in South Africa
by: Wang, M, et al.
Published: (2023)

Low CD4 count and educational status predict abnormal cervical smears amongst HIV-positive women initiating antiretroviral therapy in South Africa
by: Mthembu, N, et al.
Published: (2020)

Clinical outcomes with second-line dolutegravir in people with virological failure on first-line non-nucleoside reverse transcriptase inhibitor-based regimens in South Africa: a retrospective cohort study
by: Asare, K, et al.
Published: (2023)

Hypophosphataemia in HIV-positive patients taking non-tenofovir-containing antiretrovirals
by: Wainwright, E, et al.
Published: (2011)

Conceptualising implementation strategies in HIV research – Authors' reply
by: Drain, PK, et al.
Published: (2020)

Efavirenz-induced urolithiasis.
by: Wirth, G, et al.
Published: (2006)

Effectiveness of tenofovir/emtricitabine versus zidovudine/lamivudine in combination with efavirenz in antiretro viral-naive HIV infected patients / Siti Mahanim Shaik Ismail
by: Shaik Ismail, Siti Mahanim
Published: (2015)

Virologic response to first-line efavirenz- or nevirapine-based antiretroviral therapy in HIV-infected African children
by: Kekitiinwa, A, et al.
Published: (2017)

Diagnostic accuracy of the Alere Afinion AS100 point-of-care assay to screen for non-communicable diseases amongst people living with HIV
by: Bodley, N, et al.
Published: (2022)

Initial supplementary dose of dolutegravir in second-line antiretroviral therapy: a noncomparative, double-blind, randomized placebo-controlled trial
by: Zhao, Y, et al.
Published: (2023)

Recovery of effective hiv-specific cd4+ t-cell activity following antiretroviral therapy in paediatric infection requires sustained suppression of viraemia
by: Adland, E, et al.
Published: (2018)

Comparative cost analysis of point-of-care versus laboratory-based testing to initiate and monitor HIV treatment in South Africa
by: Simeon, K, et al.
Published: (2019)

HIV-1 RNA may decline more slowly in semen than in blood following initiation of efavirenz-based antiretroviral therapy.
by: Graham, S, et al.
Published: (2012)

Determining targets for antiretroviral drug concentrations: a causal framework illustrated with pediatric efavirenz data from the CHAPAS-3 trial
by: Schomaker, M, et al.
Published: (2024)

Adipocyte mitochondrial gene expression following 18-24 months treatment with zidovidine or tenofovir-containing antiretroviral therapy
by: McGee, K, et al.
Published: (2009)

Impact of efavirenz, ritonavir-boosted lopinavir and nevirapine based antiretroviral regimens on the pharmacokinetics of lumefantrine and safety of artemether-lumefantrine in falciparum-negative HIV-infected Malawian adults stabilized on antiretroviral therapy
by: Banda, CG, et al.
Published: (2018)

Quality of life in patients treated with first-line antiretroviral therapy containing nevirapine or efavirenz in Uganda: a prospective non-randomized study
by: Mwesigire, D, et al.
Published: (2015)

Impact of dolutegravir-based antiretroviral therapy on piperaquine exposure following dihydroartemisinin-piperaquine intermittent preventive treatment of malaria in pregnant women living with HIV
by: Banda, CG, et al.
Published: (2022)

Intimate Partner Violence and HIV Outcomes Among Women Living with HIV in Durban, South Africa
by: Ojeaburu, SO, et al.
Published: (2024)

Point-of-care viral load testing and differentiated HIV care
by: Dorward, J, et al.
Published: (2017)

Distinct genital tract HIV-specific antibody profiles associated with tenofovir gel
by: Archary, D, et al.
Published: (2017)

Differentiated service delivery for people using second-line antiretroviral therapy: clinical outcomes from a retrospective cohort study in KwaZulu-Natal, South Africa
by: Lewis, L, et al.
Published: (2021)

Pediatric underdosing of efavirenz: a pharmacokinetic study in Uganda.
by: Fillekes, Q, et al.
Published: (2011)

The impact of genetic polymorphisms on the pharmacokinetics of efavirenz in African children
by: Bienczak, A, et al.
Published: (2016)